Just a few neoantigens may be enough for T cells to control

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

What is T cell therapy?

John Gordon on LinkedIn: #immunotherapy #mrna #neoantigen #vaccine #tcells #pancreatictumours…

Role of T cells in cancer immunotherapy: Opportunities and challenges - ScienceDirect

Frontiers Neoantigen: A New Breakthrough in Tumor Immunotherapy

Unleashing Our Immune Response to Quash Cancer

Tumor Antigen Targets for Personalized Adoptive T Cell Therapies

Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)

Just a few neoantigens may be enough for T cells to control prostate cancer

CD4+ CAR T cells kill tumor cells from a distance with IFNγ

Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study